Single User License
INR 168725
Site License
INR 337450
Corporate User License
INR 506175

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Review, H1 2015

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Review, H1 2015', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 10

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 11

Therapeutics Development 12

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Therapeutics under Development by Companies 14

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Therapeutics under Investigation by Universities/Institutes 29

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline Products Glance 33

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Products under Development by Companies 37

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Products under Investigation by Universities/Institutes 62

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Companies Involved in Therapeutics Development 66

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Therapeutics Assessment 234

Drug Profiles 258

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Recent Pipeline Updates 814

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects 1177

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products 1190

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Product Development Milestones 1196

Appendix 1207

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2015 46

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Comparative Analysis, H1 2015 47

Number of Products under Development by Companies, H1 2015 49

Number of Products under Development by Companies, H1 2015 (Contd..1) 50

Number of Products under Development by Companies, H1 2015 (Contd..2) 51

Number of Products under Development by Companies, H1 2015 (Contd..3) 52

Number of Products under Development by Companies, H1 2015 (Contd..4) 53

Number of Products under Development by Companies, H1 2015 (Contd..5) 54

Number of Products under Development by Companies, H1 2015 (Contd..6) 55

Number of Products under Development by Companies, H1 2015 (Contd..7) 56

Number of Products under Development by Companies, H1 2015 (Contd..8) 57

Number of Products under Development by Companies, H1 2015 (Contd..9) 58

Number of Products under Development by Companies, H1 2015 (Contd..10) 59

Number of Products under Development by Companies, H1 2015 (Contd..11) 60

Number of Products under Development by Companies, H1 2015 (Contd..12) 61

Number of Products under Development by Companies, H1 2015 (Contd..13) 62

Number of Products under Investigation by Universities/Institutes, H1 2015 64

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 65

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 66

Comparative Analysis by Late Stage Development, H1 2015 67

Comparative Analysis by Clinical Stage Development, H1 2015 68

Comparative Analysis by Early Stage Development, H1 2015 69

Comparative Analysis by Unknown Stage Development, H1 2015 70

Products under Development by Companies, H1 2015 71

Products under Development by Companies, H1 2015 (Contd..1) 72

Products under Development by Companies, H1 2015 (Contd..2) 73

Products under Development by Companies, H1 2015 (Contd..3) 74

Products under Development by Companies, H1 2015 (Contd..4) 75

Products under Development by Companies, H1 2015 (Contd..5) 76

Products under Development by Companies, H1 2015 (Contd..6) 77

Products under Development by Companies, H1 2015 (Contd..7) 78

Products under Development by Companies, H1 2015 (Contd..8) 79

Products under Development by Companies, H1 2015 (Contd..9) 80

Products under Development by Companies, H1 2015 (Contd..10) 81

Products under Development by Companies, H1 2015 (Contd..11) 82

Products under Development by Companies, H1 2015 (Contd..12) 83

Products under Development by Companies, H1 2015 (Contd..13) 84

Products under Development by Companies, H1 2015 (Contd..14) 85

Products under Development by Companies, H1 2015 (Contd..15) 86

Products under Development by Companies, H1 2015 (Contd..16) 87

Products under Development by Companies, H1 2015 (Contd..17) 88

Products under Development by Companies, H1 2015 (Contd..18) 89

Products under Development by Companies, H1 2015 (Contd..19) 90

Products under Development by Companies, H1 2015 (Contd..20) 91

Products under Development by Companies, H1 2015 (Contd..21) 92

Products under Development by Companies, H1 2015 (Contd..22) 93

Products under Development by Companies, H1 2015 (Contd..23) 94

Products under Development by Companies, H1 2015 (Contd..24) 95

Products under Investigation by Universities/Institutes, H1 2015 96

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 97

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 98

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 99

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by 4SC AG, H1 2015 100

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by AB Science, H1 2015 101

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by AbbVie Inc., H1 2015 102

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 103

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 104

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Advenchen Laboratories, LLC, H1 2015 105

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Affichem, H1 2015 106

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 107

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by AIMM Therapeutics B.V., H1 2015 108

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Akinion Pharmaceuticals AB, H1 2015 109

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Altor BioScience Corporation, H1 2015 110

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Amgen Inc., H1 2015 111

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Antigen Express, Inc., H1 2015 112

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by APIM Therapeutics AS, H1 2015 113

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Aprea AB, H1 2015 114

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Aptose Biosciences Inc., H1 2015 115

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 116

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Arno Therapeutics, Inc., H1 2015 117

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Arog Pharmaceuticals, Inc., H1 2015 118

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Array BioPharma Inc., H1 2015 119

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Ascenta Therapeutics, Inc., H1 2015 120

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Astellas Pharma Inc., H1 2015 121

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 122

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by AstraZeneca Plc, H1 2015 123

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 124

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Bayer AG, H1 2015 125

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by BerGenBio AS, H1 2015 126

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by BIND Therapeutics, Inc., H1 2015 127

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 128

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Bio-Path Holdings, Inc., H1 2015 129

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by BioInvent International AB, H1 2015 130

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by BioLineRx, Ltd., H1 2015 131

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 132

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Boston Biomedical, Inc., H1 2015 133

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Bristol-Myers Squibb Company, H1 2015 134

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Calithera Biosciences, Inc., H1 2015 135

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 136

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cantargia AB, H1 2015 137

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 138

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Celator Pharmaceuticals, Inc., H1 2015 139

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Celgene Corporation, H1 2015 140

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cellceutix Corporation, H1 2015 141

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Celldex Therapeutics, Inc., H1 2015 142

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cellectis S.A., H1 2015 143

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cellerant Therapeutics, Inc., H1 2015 144

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Celyad, H1 2015 145

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Clevexel Pharma SAS, H1 2015 146

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Conkwest, Inc., H1 2015 147

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 148

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 149

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Critical Outcome Technologies Inc., H1 2015 150

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by CTI BioPharma Corp., H1 2015 151

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by CureTech Ltd., H1 2015 152

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 153

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 154

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by DC Prime B.V., H1 2015 155

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Debiopharm International S.A., H1 2015 156

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 157

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Egenix, Inc., H1 2015 158

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Eisai Co., Ltd., H1 2015 159

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Eli Lilly and Company, H1 2015 160

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by EntreChem, S.L., H1 2015 161

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by EpiZyme, Inc., H1 2015 162

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Erytech Pharma SA, H1 2015 163

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 164

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Eureka Therapeutics, Inc., H1 2015 165

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Exelixis, Inc., H1 2015 166

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 167

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Fate Therapeutics, Inc., H1 2015 168

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Formula Pharmaceuticals, Inc., H1 2015 169

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Fortress Biotech, Inc., H1 2015 170

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Fujifilm Corporation, H1 2015 171

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Gamida Cell Ltd., H1 2015 172

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Genentech, Inc., H1 2015 173

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Genoscience Pharma, H1 2015 174

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Genosco, H1 2015 175

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Genzyme Corporation, H1 2015 176

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Gilead Sciences, Inc., H1 2015 177

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by GlaxoSmithKline Plc, H1 2015 178

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by GlycoMimetics, Inc., H1 2015 179

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Golden Biotechnology Corp., H1 2015 180

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Hybrigenics S.A., H1 2015 181

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Igenica Biotherapeutics, Inc., H1 2015 182

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Ignyta, Inc., H1 2015 183

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Immune System Key Ltd., H1 2015 184

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by ImmunGene, Inc., H1 2015 185

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by ImmunoGen, Inc., H1 2015 186

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 187

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Incyte Corporation, H1 2015 188

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Innate Pharma SA, H1 2015 189

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Interprotein Corporation, H1 2015 190

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 191

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 192

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Johnson & Johnson, H1 2015 193

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Juno Therapeutics Inc., H1 2015 194

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by JW Pharmaceutical Corporation, H1 2015 195

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Kainos Medicine, Inc., H1 2015 196

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 197

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 198

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Kiadis Pharma B.V., H1 2015 199

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 200

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Komipharm International Co., Ltd., H1 2015 201

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 202

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Lead Discovery Center GmbH, H1 2015 203

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Les Laboratoires Servier SAS, H1 2015 204

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MacroGenics, Inc., H1 2015 205

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MaxCyte, Inc., H1 2015 206

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by medac GmbH, H1 2015 207

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MediGene AG, H1 2015 208

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MedImmune, LLC, H1 2015 209

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MEI Pharma, Inc., H1 2015 210

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Merck & Co., Inc., H1 2015 211

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Merus B.V., H1 2015 212

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 213

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Mirna Therapeutics, Inc., H1 2015 214

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by MolMed S.p.A., H1 2015 215

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 216

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Neumedicines Inc., H1 2015 217

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Novartis AG, H1 2015 218

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by NuCana BioMed Limited, H1 2015 220

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by OncoImmune, Inc., H1 2015 221

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Onconova Therapeutics, Inc., H1 2015 222

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 223

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 224

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 225

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Oxford BioTherapeutics Ltd, H1 2015 226

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by OXiGENE, Inc., H1 2015 227

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Pfizer Inc., H1 2015 228

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Pharma Mar, S.A., H1 2015 229

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Pharmacyclics, Inc., H1 2015 230

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Pharmedartis GmbH, H1 2015 231

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Philogen S.p.A., H1 2015 232

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Plexxikon Inc., H1 2015 233

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 234

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Resverlogix Corp., H1 2015 235

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Rich Pharmaceuticals, Inc., H1 2015 236

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sanofi, H1 2015 237

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sareum Holdings Plc, H1 2015 238

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Seattle Genetics, Inc., H1 2015 239

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sellas Inc., H1 2015 240

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Selvita SA, H1 2015 241

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Senhwa Biosciences, Inc., H1 2015 242

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sentinel Oncology Limited, H1 2015 243

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by SpectraMab GmbH, H1 2015 244

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Stemline Therapeutics, Inc., H1 2015 245

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 246

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 247

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 248

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by SYNIMMUNE GmbH, H1 2015 249

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Synta Pharmaceuticals Corp., H1 2015 250

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Syros Pharmaceuticals, Inc., H1 2015 251

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 252

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Tautatis Incorporated, H1 2015 253

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by TetraLogic Pharmaceuticals, H1 2015 254

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 255

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Theravectys S.A., H1 2015 256

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 257

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2015 258

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 259

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Tragara Pharmaceuticals, Inc., H1 2015 260

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Trillium Therapeutics Inc., H1 2015 261

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Verastem, Inc., H1 2015 262

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Vichem Chemie Research Ltd., H1 2015 263

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by VioQuest Pharmaceuticals, Inc., H1 2015 264

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Viralytics Ltd., H1 2015 265

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Xencor, Inc., H1 2015 266

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Pipeline by Xenetic Biosciences plc, H1 2015 267

Assessment by Monotherapy Products, H1 2015 268

Assessment by Combination Products, H1 2015 269

Number of Products by Stage and Target, H1 2015 271

Number of Products by Stage and Mechanism of Action, H1 2015 281

Number of Products by Stage and Route of Administration, H1 2015 289

Number of Products by Stage and Molecule Type, H1 2015 291

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics-Recent Pipeline Updates, H1 2015 848

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects, H1 2015 1211

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..1), H1 2015 1212

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..2), H1 2015 1213

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..3), H1 2015 1214

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..4), H1 2015 1215

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..5), H1 2015 1216

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..6), H1 2015 1217

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..7), H1 2015 1218

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..8), H1 2015 1219

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..9), H1 2015 1220

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..10), H1 2015 1221

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..11), H1 2015 1222

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Dormant Projects (Contd..12), H1 2015 1223

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products, H1 2015 1224

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products (Contd..1), H1 2015 1225

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products (Contd..2), H1 2015 1226

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products (Contd..3), H1 2015 1227

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products (Contd..4), H1 2015 1228

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Discontinued Products (Contd..5), H1 2015 1229

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2015 46

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Comparative Analysis, H1 2015 47

Number of Products under Development by Companies, H1 2015 48

Number of Products under Investigation by Universities/Institutes, H1 2015 63

Comparative Analysis by Clinical Stage Development, H1 2015 68

Comparative Analysis by Early Stage Products, H1 2015 69

Assessment by Monotherapy Products, H1 2015 268

Assessment by Combination Products, H1 2015 269

Number of Products by Top 10 Targets, H1 2015 270

Number of Products by Stage and Top 10 Targets, H1 2015 270

Number of Products by Top 10 Mechanism of Actions, H1 2015 280

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 280

Number of Products by Top 10 Routes of Administration, H1 2015 288

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 288

Number of Products by Top 10 Molecule Types, H1 2015 290

Number of Products by Stage and Top 10 Molecule Types, H1 2015 290

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Advenchen Laboratories, LLC

Affichem

Agios Pharmaceuticals, Inc.

AIMM Therapeutics B.V.

Akinion Pharmaceuticals AB

Altor BioScience Corporation

Amgen Inc.

Antigen Express, Inc.

APIM Therapeutics AS

Aprea AB

Aptose Biosciences Inc.

Ariad Pharmaceuticals, Inc.

Arno Therapeutics, Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BerGenBio AS

BIND Therapeutics, Inc.

Bio-Cancer Treatment International Limited

Bio-Path Holdings, Inc.

BioInvent International AB

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cancer Therapeutics CRC Pty Ltd

Cantargia AB

Cantex Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc.

Celgene Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Cellectis S.A.

Cellerant Therapeutics, Inc.

Celyad

Clevexel Pharma SAS

Conkwest, Inc.

Constellation Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

CTI BioPharma Corp.

CureTech Ltd.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

DC Prime B.V.

Debiopharm International S.A.

Deciphera Pharmaceuticals, LLC

Egenix, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

EpiZyme, Inc.

Erytech Pharma SA

Esperance Pharmaceuticals, Inc.

Eureka Therapeutics, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Fate Therapeutics, Inc.

Formula Pharmaceuticals, Inc.

Fortress Biotech, Inc.

Fujifilm Corporation

Gamida Cell Ltd.

Genentech, Inc.

Genoscience Pharma

Genosco

Genzyme Corporation

Gilead Sciences, Inc.

GlaxoSmithKline Plc

GlycoMimetics, Inc.

Golden Biotechnology Corp.

Hybrigenics S.A.

Igenica Biotherapeutics, Inc.

Ignyta, Inc.

Immune System Key Ltd.

ImmunGene, Inc.

ImmunoGen, Inc.

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

Innate Pharma SA

Interprotein Corporation

Jasco Pharmaceuticals, LLC.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

Juno Therapeutics Inc.

JW Pharmaceutical Corporation

Kainos Medicine, Inc.

KaloBios Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Kiadis Pharma B.V.

Kinex Pharmaceuticals, LLC

Komipharm International Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

MacroGenics, Inc.

MaxCyte, Inc.

medac GmbH

MediGene AG

MedImmune, LLC

MEI Pharma, Inc.

Merck & Co., Inc.

Merus B.V.

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

Nerviano Medical Sciences S.r.l.

Neumedicines Inc.

Novartis AG

NuCana BioMed Limited

OncoImmune, Inc.

Onconova Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

OXiGENE, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Pharmedartis GmbH

Philogen S.p.A.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Resverlogix Corp.

Rich Pharmaceuticals, Inc.

Sanofi

Sareum Holdings Plc

Seattle Genetics, Inc.

Sellas Inc.

Selvita SA

Senhwa Biosciences, Inc.

Sentinel Oncology Limited

SpectraMab GmbH

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sunesis Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.

SYNIMMUNE GmbH

Synta Pharmaceuticals Corp.

Syros Pharmaceuticals, Inc.

TaiGen Biotechnology Co., Ltd.

Tautatis Incorporated

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Toko Pharmaceutical Industries Co., Ltd.

Tolero Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Trillium Therapeutics Inc.

Verastem, Inc.

Vichem Chemie Research Ltd.

VioQuest Pharmaceuticals, Inc.

Viralytics Ltd.

Xencor, Inc.

Xenetic Biosciences plc

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutic Products under Development, Key Players in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline Overview, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com